Cosmos Holdings

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Chicago, IL.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

CHICAGO, IL / ACCESSWIRE / March 7, 2023 / Cosmos Health Inc. ("Cosmos Health" or "the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has entered into a material definitive agreement with Pharmaceutical Laboratories CANA S.A., ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

Cosmos Health Enters into a Material Definitive Agreement with Cana Laboratories

CHICAGO, IL / ACCESSWIRE / March 3, 2023 / Cosmos Health Inc. ("the Company") (Nasdaq:COSM), a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has concluded its due diligence and is in the process of preparing the definitive documentation to complete the acquisition of ZipDoctor Inc. from American International Holdings Corp (AMIH). ZipDoctor Inc., a wholly owned subsidiary of American International Holdings Corp. (AMIH), is a direct-to-consumer subscription-based telemedicine platform, that expects to provide its customers affordable, unlimited, 24/7 access to board certified physicians and licensed mental and behavioural health counsellors and therapists.

Cosmos Health Expects to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.

CHICAGO, IL / ACCESSWIRE / February 15, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended its previously issued non-binding letter of intent (LOI) to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). The parties have agreed to extend the LOI through February 24, 2023.

Cosmos Health Extends its Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.

Virax Biolabs Group Ltd

CHICAGO, IL / ACCESSWIRE / February 7, 2023 / Cosmos Health Inc. ("the Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the first purchase order to market and distribute Virax Biolabs' (Nasdaq: VRAX) ViraxClear branded COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to its previously signed distribution agreement dated September 2022, Cosmos Health will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.

Cosmos Health Announces Initial Purchase Order with Virax Biolabs for the Distribution of COVID-19 and Influenza A+B Antigen Combo Rapid Tests

LONDON , Feb. 7, 2023 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative diagnostics company focused on the prevention, detection, and diagnosis of viral diseases, announced that it has signed a Purchase Order with Cosmos Health (Nasdaq: COSM) ("Cosmos") to launch and market COVID-19 and Influenza A+B Antigen Combo Rapid Detection Kits. Pursuant to their previously signed distribution agreement dated September 2022, Cosmos will have exclusive distribution rights for Greece and Cyprus, with the opportunity to distribute the ViraxClear branded test kits across Europe on a non-exclusive basis.

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

Things have started to heat up after January 17, 2023, when Cosmos unleashed a flurry of positive news, with a total of 6 major announcements made since then. Credit needs to be given to Cosmos management. It has been a series of positive shareholder-friendly actions.

Cosmos Health: Shareholder-Friendly News Abounds, Stock Still Undervalued

CHICAGO, IL / ACCESSWIRE / February 2, 2023 / Cosmos Health Inc. (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that is has begun the application process to dual list its shares on Upstream, the trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). The planned dual listing on Upstream is designed to provide Cosmos Health the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, increasing liquidity and enhancing price discovery while globalizing the opportunity to invest in NASDAQ-listed Cosmos Health.

Cosmos Health Announces Application for Dual Listing on Upstream

CHICAGO, IL / ACCESSWIRE / February 1, 2023 / Cosmos Health Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, is pleased to announce the appointment of Nikos Bardakis, who comes with over two decades of international branded pharmaceutical sector experience, as the Chief Operating Officer (COO). As the Chief Operating Officer at Cosmos Health, Mr.

Cosmos Health Announces the Appointment of Nikos Bardakis, an Experienced Executive in the Pharmaceutical Industry, as Chief Operating Officer

CHICAGO, IL / ACCESSWIRE / January 26, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announces that in response to the data obtained through Shareholder Intelligence Services, it has retained services of Wes Christian of Christian Levine Law Group and Alan Pollack of Warshaw Burstein, LLP (the "Firms"), to help the company develop its next course of action. The Firms are premiere law firms with a strong focus in the field of naked short selling and stock manipulation.

Cosmos Health Retains Christian Levine Law Group to Further Monitor Trading Irregularities

CHICAGO, IL / ACCESSWIRE / January 24, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that its Board of Directors has approved a share repurchase program with authorization to purchase up to $3 million of its common stock. Cosmos may repurchase shares from time to time through open market purchases in accordance with applicable securities laws and other restrictions.

Cosmos Health Announces Stock Buyback Program

Tapping Into the Fast Growing Multi Billion Dollar U.S. Telehealth Market CHICAGO, IL / ACCESSWIRE / January 20, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended and updated its previously issued non-binding letter of intent to acquire ZipDoctor Inc. from American International Holdings Corp (AMIH). Cosmos Health has successfully renegotiated the acquisition price of ZipDoctor to achieve much improved payment terms.

Cosmos Health Extends and Updates its Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp

Reduced its debt by 78% from $21.2M in 2021 to $4.6M in 2022 and expects interest expense in 2023 to be $0.6M versus $2.2M in 2022. CHICAGO, IL / ACCESSWIRE / January 17, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced an update regarding its debt balance and proforma interest expense in 2023.

Cosmos Health Provides an Update on its Debt Balance and Proforma Interest Expense

In 2022, Cosmos' share price plummeted more than 90% as it was caught in the midst of market turmoil. The completion of a reverse stock split and official compliance with Nasdaq listing requirements have improved investor perception.

Cosmos Health: A Cash-Rich Small Cap With Significant Growth Ahead

Vertically Integrating its Manufacturing and R&D Capabilities and Expanding its Product Pipeline with New Brands CHICAGO, IL / ACCESSWIRE / January 10, 2023 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that it has extended and updated its previously issued binding letter of intent to acquire Pharmaceutical Laboratories CANA S.A. , ("Cana") a Greek pharmaceutical company that manufactures, sells, distributes, and markets original branded products researched and developed by leading global pharmaceutical and healthcare companies.

Cosmos Health Extends and Updates its Agreement to Acquire Cana Laboratories, a European Pharmaceutical Company

AST SpaceMobile

180 Life Sciences 

Canoo

IMARA

Marathon Digital Holdings

Redfin

Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?

Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch

Short Squeeze Penny Stocks To Watch At The Start Of 2023. The post Penny Stocks To Buy This Week?

Penny Stocks To Buy This Week? 4 Short Squeeze Stocks To Watch

Re-affirming His Commitment to Growth and Profitability CHICAGO, IL / ACCESSWIRE / December 22, 2022 / Cosmos Health, Inc. ("the Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, announced today that CEO Greg Siokas has participated with $3 million in the approximately $32.5 million financing of the Company completed yesterday, December 21, 2022, increasing to approximately $6 million his personal investments in the Company throughout 2022. Greg Siokas, Chief Executive Officer of Cosmos Health stated, "I continue to be dedicated to the growth and future profitability of Cosmos Health.

Cosmos Health CEO Participated in the Last Fundraising of the Company

CHICAGO, IL / ACCESSWIRE / December 21, 2022 / Cosmos Health Inc. (the "Company") (NASDAQ:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced the closing of its previously announced registered direct offering of 2,828,320 shares of the Company's common stock and concurrent private placement of warrants to purchase 2,828,320 shares of the Company's common stock at a combined purchase price of $11.50. The warrants have an exercise price of $11.50 per share, are exercisable immediately and expire five years from the issuance date.

Cosmos Health Inc. Announces Successful Closing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market

Cosmos Health Inc.'s stock pulled back Monday after the company announced the pricing of a $32.5 million registered direct offering, wiping away Friday's big gains.

Cosmos Health stock tumbles, weighed down by $32.5 million registered direct offering

Cosmos Health (NASDAQ: COSM ) stock is falling hard on Monday after the healthcare company's shares got a boost on Friday. That increase in price for COSM stock came alongside a couple of pieces of news from the company.

Why Is Cosmos Health (COSM) Stock Down 58% Today?

CHICAGO, IL / ACCESSWIRE / December 19, 2022 / Cosmos Health Inc. (the "Company") (Nasdaq:COSM) , a global healthcare group with proprietary lines of nutraceuticals and distributor of pharmaceuticals, branded generics, OTC medications and medical devices, today announced that it has entered into securities purchase agreements with institutional investors for the purchase and sale of 2,828,320 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 2,828,320 common shares in a concurrent private placement. The combined purchase price for one share of common stock and one warrant will be $11.50.

Cosmos Health Inc. Announces Pricing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market

Cosmos Health Inc.'s stock price nearly tripled Friday as investors responded to the company's reverse stock split.

Cosmos Health stock rockets on reverse stock split

Cosmos (NASDAQ: COSM ) stock is on the move Friday as the healthcare company undergoes a name change and a reverse stock split today. The name change saw the company moving from the Cosmos Holdings name to its new Cosmos Health name.

COSM Stock Alert: What to Know As Cosmos' Reverse Stock Split Takes Effect

Core Scientific Inc

Troika Media Group

Use these methods to find penny stocks The post Top Methods for Building A Penny Stocks Portfolio  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Methods for Building A Penny Stocks Portfolio

Ambrx Biopharma Inc

ComSovereign Holding

Use these tips for evaluating penny stocks to buy The post How to Find and Evaluate Penny Stocks For Your Portfolio  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Cosmos Holdings Stock (COSM)